Peptides: Promising Science, Big Claims, and Why I’m Still on the Fence

When you have been struggling with fatigue, pain, brain fog, or other persistent symptoms, the idea of a treatment that could make everything go away is incredibly appealing.

I understand that appeal. People want to feel better. They want their energy back, their bodies back, and their lives back. After months or years of searching for answers, a treatment promising faster healing, better sleep, less inflammation, and renewed vitality can sound like exactly what they have been waiting for.

Peptides have become a major part of that conversation.

Patients ask me about them regularly, and many of my patients have tried them. I remain interested in the science. But so far, what I have seen—and what the research shows—has not convinced me enough to routinely recommend the experimental peptides being promoted for healing, recovery, and longevity.

Here is why.

What Are Peptides?

Peptides are short chains of amino acids, the building blocks of proteins. Some act as messengers, helping cells communicate and influencing processes such as hormone release, metabolism, and tissue repair.

The term covers a wide range of substances. Some peptide medications have substantial clinical evidence and clearly defined medical uses. Semaglutide, for example, has demonstrated benefits for weight management and has an FDA-approved indication for reducing cardiovascular events in certain patients. That evidence cannot automatically be extended to other substances simply because they are also peptides.

When people talk about “peptide therapy” in the wellness world, they are often referring to experimental products with a much less developed evidence base.

What Does the Research Show About Commonly Discussed Peptides?

BPC-157: Tissue Repair and “Gut Healing”

BPC-157 is frequently promoted for tendon injuries, joint pain, and digestive problems. Animal research has produced encouraging findings involving tissue repair.

Human evidence is much thinner. A 2025 review of its musculoskeletal uses included 35 preclinical studies and just one clinical study. That human study was a small retrospective report of knee injections, rather than a rigorous trial comparing treatment with placebo. Some patients reported improvement, but that design cannot reliably establish how much benefit came from the peptide itself. These findings also do not establish that BPC-157 heals digestive problems in humans.

TB-500 and Thymosin Beta-4: Recovery and Healing

These names often appear in discussions of injury recovery. However, research involving full-length thymosin beta-4 should not be treated as proof that products marketed as TB-500 have the same effects.

There has been human research on a thymosin beta-4 eye-drop formulation. In one randomized study of 72 people with dry eye, the treatment did not significantly improve the two primary outcomes, although several secondary measures improved. That is a reason for further investigation. It does not establish that injecting TB-500 repairs tendons or provides whole-body rejuvenation.

CJC-1295, Ipamorelin, and Sermorelin: Growth Hormone Signaling

These substances are discussed as ways to stimulate growth hormone release, often with claims about muscle, sleep, energy, and aging.

A small, short-term randomized study showed that CJC-1295 increased growth hormone and IGF-1 levels in healthy adults. That demonstrates a biological effect. It does not establish that treatment improves long-term health or extends life. Research on one compound or formulation also cannot validate every combination sold under a similar name.

Ipamorelin has been studied in people recovering from bowel surgery, but that very specific setting does not establish its usefulness for general wellness or anti-aging. Each of these substances needs evidence for the particular use being proposed.

AOD-9604: Fat Loss

AOD-9604 is a modified fragment of growth hormone marketed for fat loss. Its clinical history is less impressive than its advertising might suggest.

An FDA review described a large oral-treatment trial that enrolled 536 adults and failed to demonstrate a significant weight-loss advantage over placebo at its primary endpoint. The company subsequently ended development for obesity. Those results do not support assuming that currently marketed injections are effective.

Thymosin Alpha-1: Immune Support

Thymosin alpha-1 has been investigated in specific illnesses involving immune dysfunction. It has more human research than several other wellness peptides, but the findings are not uniformly positive.

A large randomized trial in adults with sepsis found no significant improvement in 28-day mortality. That does not settle every possible use, but it illustrates why “supports the immune system” is too broad a claim to guide treatment. Evidence in hospitalized patients also does not establish that it treats persistent fatigue or unexplained symptoms in an outpatient setting.

GHK-Cu: Skin Care and Regeneration

GHK-Cu is a copper-binding peptide studied in skin-related research and used in cosmetic products. Laboratory work has investigated its behavior in human skin, including penetration through the skin barrier. That is different from demonstrating meaningful clinical benefits from injections.

The FDA has specifically identified concerns about injectable GHK-Cu, including potential immune reactions and limited human safety information. A topical cosmetic and an injectable treatment should be evaluated separately.

MOTS-c: Metabolism, Energy, and Longevity

MOTS-c is a peptide associated with mitochondria, the structures involved in cellular energy production. Research has explored its relationship with exercise and metabolism.

An important distinction is that measuring the body’s own MOTS-c response to exercise is different from proving that injecting it improves health. Studies combining human observations with treatment experiments in animals can be scientifically interesting without establishing an effective human treatment.

Across these examples, the recurring gap is between an interesting mechanism and a proven clinical benefit.

Why These Treatments Raise Red Flags for Me

I become cautious when a treatment combines:

That pattern does not prove a treatment is ineffective. It does mean I want stronger evidence before recommending it.

The ongoing-treatment question requires some nuance. Many legitimate therapies need to be continued because they manage a chronic condition. Needing maintenance treatment does not automatically make a therapy a bad choice.

But when experimental peptides are sold with the message that you must keep taking them to preserve your benefits, I want to know what supports that claim. For many of these uses, we do not have good studies showing how durable the benefits are, whether repeated courses are necessary, or what years of exposure might mean.

I also want to know whether the benefit is large enough to justify the cost—and whether the same money could do more for the patient elsewhere.

My Experience Has Not Yet Convinced Me

I have had many patients try peptide treatments. Their experiences matter, and I take reports of improvement seriously.

Still, I have not seen enough consistent, convincing benefit to make these experimental treatments a routine recommendation in my practice.

My observations are not a controlled study. Patients may change several treatments at once, symptoms can fluctuate, and an individual response cannot answer every question about safety or effectiveness. But clinical experience does influence how comfortable I feel recommending something, particularly when the research remains limited.

Safety Goes Beyond the Peptide Itself

Safety also involves more than the peptide’s intended action. The things that matter include:

• Product purity and sterility
• Formulation and dose consistency
• Potential immune reactions and impurities
• Adequate information about the specific injection route

The FDA has identified safety concerns for several experimental peptides. Limited reports of harm should not be mistaken for proof of long-term safety.

Why I Keep Returning to Root Cause Management

In my experience, lasting progress usually requires understanding what is continuing to make the person unwell.

At Restorative Medicine Center, that includes considering microbes, environmental toxins, and stress when the history and clinical findings suggest they may be relevant. It also means evaluating sleep, nutrition, metabolic health, hormonal problems, and other medical conditions.

These are not universal explanations for every symptom. They are areas to investigate thoughtfully rather than assume.

If an infection, ongoing exposure, or sustained stress response is contributing to illness, a treatment aimed at improving recovery may leave that underlying problem unresolved. Symptom relief can still be valuable, but I want it to fit into a plan that addresses the drivers we can identify.

That work often takes time. It can involve several steps and adjustments along the way. I understand why something that sounds faster and easier is so attractive.

I remain open to peptides earning a clearer place in care as better research becomes available. For now, I am still on the fence about the experimental treatments marketed for broad healing and longevity. Before asking patients to make an expensive, potentially ongoing commitment, I want convincing evidence of meaningful benefit, reasonable safety, and a clear purpose within their treatment plan.

My priority remains helping patients understand what is keeping them unwell and building a path toward health that they can sustain.

For more honest takes on wellness trends and root-cause healing, follow Restorative Medicine Center on Facebook.